It is with great pleasure that we announce Dr. Lakshmi (Priya) Kunju as our new Director of the Division of Anatomic Pathology (AP) effective Wednesday, March 1, 2023. We are grateful for all that Dr. Kunju brings to the table including her considerable experience with operations across the division and her willingness to jump in on short notice to ensure stability during this transition. She will work with department leaders and others to identify and recruit to her role as Section Head for Surgical Pathology and Medical Director of our gross room and histology laboratory. Please join us in congratulating Dr. Priya Kunju on her appointment as AP Director. Please also join us in thanking Dr. Liron Pantanowitz for his nearly 3 years as AP Director. He has been remarkably productive in his role and can be proud of a division that is among the VERY BEST team of AP faculty, staff, and learners in the world!
The University of Michigan Rogel Cancer Center researchers received one of the Prostate Cancer Foundation’s four inaugural Class of 2022 TACTICAL (Therapy ACceleration To Intercept Cancer Lethality) Award. This $30 million program will support cross-disciplinary pioneering research toward the goal of developing 21st Century therapies for the most life-threatening form of prostate cancer [...]
Members of the University of Michigan Department of Pathology and Michigan Center for Translational Pathology, in collaboration with the Clinical Proteomic Tumor Analysis Consortium, recently published a large study on clear cell renal cell carcinomas (ccRCCs), which represent about 75% of the RCC cases and account for the most RCC-associated deaths. This study set out to create a comprehensive profile of ccRCC, combining histologic and molecular profiles. By analyzing both the microscopic cell structures and the genetic makeup of the cells, these researchers discovered significant intratumoral heterogeneity in 90% of ccRCCs. This indicates that ccRCCs originate from multiple tumor cell lines, called tumor subclones, that may become metastatic and could independently influence response to therapies. Through this study, the team was able to molecularly stratify aggressive histopathic subtypes, which may lead to more effective treatment strategies for patients and improved survival.
A research team from the Michigan Center for Translational Pathology undertook a study to illustrate how careful assessment of cytologic and biomarker features may provide physicians with information on Metastatic Prostatic Cancer (MCP) patients’ prognosis and the best therapies to consider [...]
Patients with relapsed multiple myeloma are resistant to commonly used treatments. Researchers are one step closer to understanding the genetic reason why.
The role of artificial intelligence (AI) in healthcare continues to expand. In a recent issue of BMC Cancer, Dr. Vipulkumar Dadhania (first author) and colleagues published a result of their study Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer. The expert team from the Michigan Center for Translational Pathology developed a deep-learning-based model to predict ERG genomic rearrangements in prostatic adenocarcinomas using only H&E-stained digital slides [...]
The Royal Swedish Academy of Sciences, which also awards the Nobel Prizes, announced today that Arul Chinnaiyan, MD, PhD, S.P. Hicks Professor of Pathology and Urology at Michigan Medicine and Director of the Michigan Center for Translational Pathology, has been selected as [...]
A chromatin degrader stops transcription factors from driving cancer, which may serve as a potential treatment approach for over 90% of prostate cancers.
The SARS-CoV-2 virus brought lab testing to the headlines. Learn how Michigan Medicine Pathology responded to this unprecedented challenge.
Dr. Xiao-Ming (Mindy) Wang and colleagues from the Michigan Center for Translational Pathology and Department of Pathology published a groundbreaking finding from an inter-institutional study regarding TRIM63 in Modern Pathology [...]
Findings offer clues to why some types of renal cell carcinoma respond to immunotherapy while others do not — it’s a scientific riddle tangled up in a complex web. How do you turn an immune cold cancer into one that responds to immunotherapy?
Not all kidney cancers behave the same, with wildly different responses to immunotherapy or other treatments – and wildly different outcomes for patients as a result. By sequencing the RNA of individual cells within multiple benign and cancerous kidney tumors, researchers from the University of Michigan Rogel Cancer Center have identified the cells [...]
Stopping the interaction between KRAS and the protein AGO2 slowed tumor growth in mouse models.
Congratulations to Arul Chinnaiyan, MD, PhD, who was announced as the Science of Oncology Award and Lecture recipient by the American Society of Clinical Oncology (ASCO). As part of this award, Chinnaiyan will present a 30-minute lecture entitled “Exploring Precision Oncology: from Gene Fusions to Related Genetic Drivers“ at the ASCO Annual Meeting, to be held virtually on June 4-8, 2021 [...]
Congratulations to Arul Chinnaiyan, MD, PhD, who was announced as the Science of Oncology Award and Lecture recipient by the American Society of Clinical Oncology (ASCO). As part of this award, Chinnaiyan will present a 30-minute lecture entitled “ “ at the ASCO Annual Meeting, to be held virtually on June 4-8, 2021.
MiTF renal cell carcinoma can masquerade as other subtypes and may not respond as well to front-line therapies.
A new study, led by U-M graduate in molecular and cellular pathology Dr. Andi Cani, was just published in European Urology Oncology. The publication focuses on the development of a whole-urine, multiplexed, next-generation RNA-sequencing assay that is used for the early detection of aggressive forms of prostate cancer [...]
Dr. Mehra discusses his career path and how he arrived at Michigan Medicine in our latest Careers in Pathology video.
Research team discovered that proteins with the capacity to multimerize quickly responded to osmotic changes (dehydration) caused by high saline or sugar concentrations, condensing into aggregates resembling processing bodies (P-bodies). The reaction, known as hyperosmotic phase separation, or HOPS, takes only a few seconds and is reversible within less than 2 minutes [...]
A new publication, generated by Department of Pathology faculty members Drs. Aaron Udager and Scott Tomlins was successfully published in European Urology. The research highlights a longitudinal cohort study centered around the serial molecular profiling of low-grade prostate cancer in order to better assess tumor upgrading [...]
Clinical trials underway are testing whether drugs that target the androgen receptor – successful in controlling prostate cancer – could also work against the coronavirus. wo proteins, ACE2 and TMPRSS2, help the coronavirus gain entry and replicate within cells. TMPRSS2 is well-known to Arul Chinnaiyan, MD, PhD. His lab discovered that TMPRSS2 fuses with the ETS gene to drive more than half of all prostate cancers [...]
The research was just published in Modern Pathology and highlights the importance of next-generation sequencing within oncogenic roles for P53 and JAK/STAT signaling in microcystic adnexal carcinomas.
The protein Argonaute 2 was found to be critical to the progression from benign lesions into pancreatic cancer, suggesting a therapeutic opportunity.
The research, which focuses on invasive squamous cell carcinomas and the precursor lesions that demonstrate concordic genomic complexity in driver genes, was just published in Modern Pathology.
The research was just published in Histopathology and features prominent contributions from our faculty.
Congratulations to Arul M. Chinnaiyan, MD, PhD, on his election to the National Academy of Science! Chinnaiyan is an investigator, Howard Hughes Medical Institute; and S.P. Hicks Endowed Professor of Pathology, American Cancer Society Research Professor, and director, Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor [...]
Marcin Cieslik, Assistant Professor of Pathology and Computational Medicine and Bioinformatics and member of the Michigan Center for Translational Pathology (MCTP), received an award from Bristol-Myers Squibb (BMS) for the project entitled, “Identification of novel therapeutic vulnerabilities across immunophenotypes of refractory and metastatic tumors.” This award provides two years of funding.
Department faculty outreach to high school students to educate about careers in medicine and research.
Two Michigan Medicine Fellows, Caroline Simon, MD, and Stephanie Skala, MD, (who recently joined the Department of Pathology as faculty), joined colleagues from the Michigan Center for Translational Pathology, in a research study published in Diagnostic Pathology dated October 21, 2019 [...]
A new study finds that U-M-designed compounds led to significantly smaller, slower-growing tumors.
If a picture's worth a thousand words, a video is perhaps worth much more.
Rohit Mehra, MD—faculty perspective on the need to understand why a patient’s cancer would not respond to treatment.
A recent collaborative study out of the Michigan Center for Translational Pathology (MCTP) has led to new insight into kidney cancer. The resulting paper, VSTM2A Overexpression is a Sensitive and Specific Biomarker for [...]